Ruxolitinib

Ruxolitinib is a selective JAK1 and JAK2 inhibitor and active pharmaceutical ingredient used in the treatment of myelofibrosis and polycythemia vera. Mediocon Inc supplies high-purity Ruxolitinib API conforming to IP / BP / EP / USP specifications from our GMP-certified facility in Aurangabad, Maharashtra, India.

Ruxolitinib inhibits the Janus kinase signaling pathway (JAK-STAT), reducing cytokine-mediated proliferation and survival signals implicated in myeloproliferative neoplasms. It is also approved for atopic dermatitis (topical form) and steroid-refractory graft-versus-host disease (GvHD).

Key Features

• High-purity pharmaceutical grade API
• IP / BP / EP / USP compliant
• Full CoA and MSDS documentation
• GMP certified manufacturing

Applications

• Myelofibrosis treatment
• Polycythemia vera management
• Graft-versus-host disease (GvHD)
• Atopic dermatitis (topical formulations)

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings